Contraindicated (one)bortezomib will enhance the level or impact of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may possibly maximize mavacamten systemic publicity, causing coronary heart failure on account of systolic dysfunction. To lower the risk of dizziness and lightheadedness, rise up little by little https://allant998eqa1.slypage.com/profile